Daewoong Pharmaceutical Signs Supply Agreement for Puzzle AI's 'CL Note'

Integrated Platform for Automated Voice Recognition-Based Medical and Nursing Records
Expanding Digital Healthcare Portfolio by Linking with 'thynC'

Daewoong Pharmaceutical has signed a supply agreement with medical artificial intelligence (AI) company Puzzle AI for the AI medical record integration solution 'CL Note' and will begin sales targeting hospitals and clinics nationwide.

Kim Yongsik, CEO of Puzzle AI (left), and Lee Changjae, CEO of Daewoong Pharmaceutical, are signing a supply contract. Daewoong Pharmaceutical

On April 28, Daewoong Pharmaceutical announced that it has secured the rights for distribution, sales, and marketing of CL Note, developed by Puzzle AI, utilizing its own sales network. Puzzle AI will be responsible for solution development and technical support. Last June, the two companies, together with Sears Technology, signed a three-party memorandum of understanding (MOU) for joint development of a smart hospital solution. In September of the same year, Daewoong Pharmaceutical made a strategic investment.

CL Note is a product that integrates the voice recognition-based medical record solution 'PuzzleGen', the nursing record solution 'PuzzleENR', and the patient call system 'Smart Call Bell' into a single platform. PuzzleGen recognizes the medical staff's voice in real time and uses generative AI to summarize and structure the consultation details, which are then automatically linked to the electronic medical record (EMR). According to the company, the accuracy of medical terminology speech-to-text conversion exceeds 98%.

PuzzleENR enables nurses to create and transmit nursing records while moving around the ward using mobile devices, and Smart Call Bell allows patients to make requests to medical staff via smartphone voice commands, with reasons and urgency checked in real time.

Puzzle AI is currently supplying its AI voice recognition solutions to about 200 medical institutions in Korea. The company stated that its solutions have been adopted by major tertiary hospitals, including Asan Medical Center, Samsung Medical Center, Severance Hospital, Seoul National University Hospital, and Seoul St. Mary's Hospital. Overseas, Puzzle AI is conducting joint research with the Mayo Clinic platform in the United States and is carrying out proof-of-concept (PoC) and demos at medical institutions in the United States, Japan, and Saudi Arabia. The company plans to ramp up its overseas market expansion starting in the second half of this year.

Changjae Lee, CEO of Daewoong Pharmaceutical, stated, "We will link CL Note with our existing smart bed monitoring system 'thynC' to provide integrated solutions for medical institutions." Kim Yongsik, CEO of Puzzle AI, said, "We will expand the adoption of our solutions among domestic medical institutions through Daewoong Pharmaceutical's sales network and expand globally."

This content was produced with the assistance of AI translation services.